Carlyle finds its first big biotech bet after teaming with Abingworth

Amber Tong

Carlyle Group and Abingworth are putting their combined powers to use, extending a custom financing deal to an Australian public company that’s in the middle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Carlyle finds its first big biotech bet after teaming with Abingworth

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Car­lyle finds its first big biotech bet af­ter team­ing with Abing­worth

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Carlyle finds its first big biotech bet after teaming with Abingworth